Isleworth (NASDAQ:ISLE) announced this afternoon that it has mutually terminated its combination agreement with biopharmaceutical company Cytovia.
Although the press release was short on details, it is likely the parties decided to terminate for the same reason a number of other SPACs recently have, which pertains to the headwinds in the SPAC market as well as general market volatility. The termination is effective immediately, but it’s worth noting that Isleworth stated that it is, “currently assessing whether it should extend its life”.
Isleworth originally brought about $207 million into the deal from its current trust, which it planned to supplement with $100 million in additional funding. As a part of this, Cytovia’s strategic partner Cellectis had agreed to invest $20 million convertible notes in the company, which were to come with a number of warrants equal to 35% of the number of shares Cellectis receives. The SPAC had a minimum cash closing condition of $50 million through a combination of its trust and the PIPE.
Isleworth had also arranged a $20 million PIPE investment to be available at the merger’s signing from new investors and had plans to line up $30 million more in PIPE investments and $30 million more convertible notes funding before close.
But, with a deadline of August 30, quickly approaching, the SPAC, as mentioned above, is still assessing whether it should extend its timeline and seek an alternative business combination. Isleworth raised $180 million at IPO on February 24, 2021 and initially aimed to combine with a revenue generating US healthcare company with direct-to-patient initiatives. The SPAC is led by Chairman Allen Weiss and CEO Robert Whitehead alongside CFO and EVP Dan Halvorson.
Both the SPAC and equity market conditions are creating an ongoing challenge for SPACs and IPOs alike, making Isleworth’s deal the 26th to terminate this year. The SPAC initially announced its $367 million combination with Cytovia earlier this year on April 27. The Aventura, Florida-based company is working to develop a range of therapies to treat liver cancer with modified natural killer cells.
At the SPAC of Dawn Several de-SPACs have made market-moving announcements recently and they haven’t forgotten to cash in on them. Fresh off of announcing $500 million strategic investment and partnership with Apple (NASDAQ:AAPL), rare earth miner MP Materials (NYSE:MP) has followed that up with a $500 million public offering, netting the company a cool...
Pyrophyte Acquisition Corp. II (NYSE:PAII.U) announced the pricing of its $175 million IPO and its units are expected to begin trading on the NYSE under the symbol “PAII.U”, Thursday, July 17, 2025. The new SPAC plans to focus its search on companies within the energy sector that constitute critical links in the supply chain of the...
At the SPAC of Dawn Rare earth miner MP Materials (NYSE:MP) was one of the early winners of the 2020 SPAC boom, having picked up momentum following its 2020 deal with Fortress Value. But, the company’s news that it will become a major supplier of battery materials for Apple’s empire of electronic devices has sent...
Solarius Capital Acquisition Corp. (NASDAQ:SOCAU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “SOCAU”, Wednesday, July 16, 2025. The new SPAC plans to combine with a target in the asset management, wealth management or financial services industries. Solarius Capital’s management team...
Exciting new things are coming for SPACInsider subscribers, and some have already arrived! This summer, SPACInsider is unveiling the SPACInsider Alerts App on iOS with an Android launch soon to follow. The app allows subscribers to stay ahead of the SPAC market with real-time, customizable filing alerts with instant notifications landing the moment that a...